paricalcitol + atorvastatin

Paricalcitol + atorvastatin is a combination of two pharmaceutical agents, each with distinct mechanisms and indications. Paricalcitol is a synthetic vitamin D analog primarily used to treat secondary hyperparathyroidism in patients with chronic kidney disease by selectively activating the vitamin D receptor, thereby reducing parathyroid hormone (PTH) synthesis and secretion. Atorvastatin is an HMG-CoA reductase inhibitor (statin) indicated for lowering cholesterol and triglyceride levels to reduce cardiovascular risk; it works by inhibiting the enzyme responsible for cholesterol biosynthesis in the liver. There are no known fixed-dose combination products of these two drugs marketed under a unique brand name or as a standard therapy; their co-administration may occur in clinical practice when both indications coexist, but this is not an approved or established combination product[2][3][7].